Peter Blume-Jensen
President and CEO at Acrivon Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Acrivon Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Acrivon Therapeutics Inc. June 13, 202599.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 25, 2026 | Acrivon Therapeutics Inc. | Open-market sale | −14,036 | $2.21 | $31,020 |
| May 18, 2026 | Acrivon Therapeutics Inc. | Grant or award | +180,095 | — | — |
| May 18, 2026 | Acrivon Therapeutics Inc. | Grant or award | +72,706 | — | — |
| May 14, 2026 | Acrivon Therapeutics Inc. | Shares withheld for tax | −1,253 | $1.92 | $2,406 |
| May 14, 2026 | Acrivon Therapeutics Inc. | Shares withheld for tax | −490 | $1.92 | $941 |
| Feb 21, 2026 | Acrivon Therapeutics Inc. | Shares withheld for tax | −14,265 | $1.53 | $21,825 |
| Feb 14, 2026 | Acrivon Therapeutics Inc. | Shares withheld for tax | −1,302 | $1.63 | $2,122 |
| Feb 14, 2026 | Acrivon Therapeutics Inc. | Shares withheld for tax | −579 | $1.63 | $944 |
| Jan 14, 2026 | Acrivon Therapeutics Inc. | Open-market purchase | +49,000 | $1.68 | $82,320 |
| May 21, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | −19,904 | $1.15 | $22,890 |
| May 14, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | −59,766 | $1.14 | $68,133 |
| May 14, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | −491 | $1.14 | $560 |
| Feb 21, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | −19,904 | $5.54 | $110,268 |
| Nov 14, 2024 | Acrivon Therapeutics Inc. | Shares withheld for tax | −59,766 | $7.92 | $473,347 |
| Nov 14, 2024 | Acrivon Therapeutics Inc. | Shares withheld for tax | −490 | $7.92 | $3,881 |
Questions about Peter Blume-Jensen
What boards is Peter Blume-Jensen on?
Peter Blume-Jensen sits on the board of Acrivon Therapeutics Inc.
What company is Peter Blume-Jensen the CEO of?
Peter Blume-Jensen is President and CEO of Acrivon Therapeutics Inc.
How long has Peter Blume-Jensen served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.